About

Who We Are

We are committed to our vision of transforming lives and making hope a reality for patients with cancer.

Daniel J. O’Connor
President, Director & Chief Executive Officer

Mr. O’Connor is the Chief Executive Officer of OncoSec Medical, Inc., a biopharmaceutical company developing intratumoral cancer immunotherapies.

Most recently, he served as President and Chief Executive Officer of Advaxis Immunotherapies, Mr. O’Connor successfully turned around the company, raising more than $250 million in funding and transforming it into a patient-focused, leading cancer immunotherapy company.  He was also instrumental in establishing major partnerships with companies that include Amgen Inc., Merck & Co. and Bristol Myers Squibb. In addition, under his leadership, the company advanced four new cancer immunotherapy drug candidates into clinical trials, as well as several PD-1 combination clinical studies with Keytruda® and Opdivo®.  Previously, Mr. O’Connor was Senior Vice President for ImClone Systems where he supported the clinical development, launch, and commercialization of ERBITUX®, and the sale of the company to Eli Lilly in 2008. Mr. O’Connor served as General Counsel at PharmaNet (inventive Health) and was part of the senior leadership team that grew the company from a start-up contract research organization into a leader in clinical research.

Mr. O’Connor is a 1995 graduate of the Penn State University’s Dickinson School of Law in Carlisle, Pennsylvania and currently serves as an Entrepreneur Trusted Advisor to its Dean. He graduated from the United States Marines Corps Officer Candidate School in 1988 and was commissioned as an officer in the U.S. Marines, attaining the rank of Captain while serving in Saudi Arabia during Operation Desert Shield. Mr. O’Connor is currently the Vice Chairman of BioNJ and was a former New Jersey criminal prosecutor.

Christopher G. Twitty, PhD
Chief Scientific Officer

Dr. Twitty brings over 20 years of experience in tumor immunology and cancer immunotherapy, including the discovery and development of OncoSec’s leading clinical immune monitoring and biomarker program.

Dr. Twitty earned his PhD from Oregon Health & Science University where his work was focused on novel tumor vaccine strategies and was awarded an American Cancer Society fellowship training grant for his post-doctoral studies in Dr. Bernard Fox’s Molecular Tumor Immunology Laboratory. After developing a preclinical and clinical immunological program focused on glioblastoma at Tocagen, Dr. Twitty joined Oncosec. Previously, Dr. Twitty held scientific positions of increasing responsibility at Bayer Pharmaceuticals and Cell Genesys, Inc.

Sara Bonstein, MBA
Chief Financial Officer & Chief Operating Officer

Ms. Bonstein brings more than 15 years of operational and financial leadership in the life sciences industry with Advaxis, Inc., Eli Lilly & Company, ImClone Systems, and Johnson & Johnson.

Ms. Bonstein has extensive experience in leading biotech companies. Prior to joining OncoSec, Sara served as the Chief Financial Officer, Secretary, Treasurer and Executive Vice President at Advaxis, Inc., where she raised approximately $300 million in the capital marketplace and licensing deals. She established strong financial controls and streamlined business operations, was responsible for the overall leadership and management of its operations, including corporate finance, investor relations, business development, IT, facilities, legal and human resources. While at Eli Lilly & Company, Sara was a Six Sigma Champion and Black Belt. Prior to her Six Sigma role, Sara was the Director of Finance where she led all budget and forecast activities for preclinical, clinical and manufacturing research and development. Prior to joining ImClone, Sara was a financial analyst at Johnson & Johnson.

Ms. Bonstein earned a bachelor’s of science degree in finance with a minor in economics from The College of New Jersey and a M.B.A. from Rider University.

Kellie Malloy Foerter
Chief Clinical Development Officer

Ms. Malloy Foerter brings nearly thirty years of experience in clinical research with Syneos Health, inVentiv Health (previously PharmaNet), and Covance.

Prior to joining OncoSec Kellie served as Executive Vice President and General Manager, Clinical Solutions at Syneos Health. As a member of the Syneos Health Clinical executive leadership team, Ms. Malloy Foerter was responsible for the development and growth of multiple portfolios across therapeutic areas which included a strong focus on oncology and hematology trials, for the world’s leading biopharmaceutical companies.  Earlier, Ms. Malloy Foerter spent 20 years at inVentiv Health (previously PharmaNet) where she held multiple positions of increasing responsibility, most recently serving as Senior Vice President, Clinical Research.  Prior to inVentiv, she served as Senior Project Associate, Clinical Research Associate and Clinical Studies Assistant at Covance.

Ms. Malloy Foerter has a Bachelor of Science degree from Saint Joseph’s University in Philadelphia, PA.

Robert W. Ashworth, Ph.D
Vice President, Regulatory

With more than 35 years of experience in the pharmaceutical industry, Dr. Ashworth is well-versed in drug development and global regulatory strategies and has made significant contributions to the FDA approval of 12 new drugs.

Prior to joining OncoSec, Dr. Ashworth served as Vice President, Regulatory Affairs, Quality & Compliance for Advaxis, Inc., where he developed and executed the global regulatory strategy for the company’s immunotherapy platform and served as the company’s regulatory representative for clinical development programs involving Amgen, Bristol-Myers Squibb and Merck. Importantly, Dr. Ashworth was instrumental in securing a groundbreaking investigational new drug application (IND) for a personalized medicine, neo-epitope program. Before Advaxis, Dr. Ashworth was Vice-President, Global Regulatory Affairs at NPS Pharmaceuticals, Inc., where he built the company’s international regulatory department and was instrumental in negotiating the approval of NATPARA (PTH) for hypoparathyroidism. As Vice-President, Global Regulatory Affairs for Otsuka Pharmaceutical Development, Inc., Dr. Ashworth was responsible for the regulatory strategy for the company’s flagship product, ABILIFY®. Dr. Ashworth’s career experience also includes regulatory positions at Biovail Corporation, Forest Laboratories, Inc., Knoll Pharmaceutical Company (BASF), and CIBA-Geigy Corporation.

Dr. Ashworth earned a B.S. in Chemistry from St. John’s University and his Ph.D. in Organic Chemistry from MIT.